GlassScriptPhysician profile
Pravin Pratap
NPI 1811105810
$13,010.37
in general payments reported to CMS, 2019-2025
48 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,022 · 2020: $1,234 · 2021: $1,655 · 2022: $1,694 · 2023: $3,391 · 2024: $1,502 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,531 · Travel and Lodging: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,530.96 |
| Travel and Lodging | $1,874.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,601.84 | 2021-2025 | Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $1,574.24 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,173.03 | 2019-2024 | Xarelto |
| Pfizer INC. | $858.38 | 2019-2025 | |
| Amgen INC. | $764.64 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $644.14 | 2019-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $574.94 | 2020-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $573.52 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $527.33 | 2021-2025 | Verquvo, Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.43 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $390.79 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $373.25 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $293.98 | 2020-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $228.47 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Lexicon Pharmaceuticals, INC. | $182.86 | 2023-2024 | Inpefa |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pravin Pratap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.